US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares slump
The US FDA declined to approve Capricor Therapeutics' experimental cell therapy, deramiocel, for Duchenne muscular dystrophy due to data integrity issues in a key clinical trial. The company's shares fell 72% in extended trading. The FDA's decision follows a previous advisory panel vote against the therapy's effectiveness in heart disease.
How this was made

The 30-second read
Why it matters
The FDA’s refusal, citing serious data integrity problems, is a direct regulatory outcome that undermines the lead asset’s approval probability and forces investors to reassess timelines, costs, and strategic options.
Market read
A clear FDA non-approval with a stated trial-quality reason drives immediate repricing and increases uncertainty around Capricor’s next regulatory steps.
What to watch
The article notes an amended application focused on upper-limb function; traders may need to monitor whether FDA feedback implies a feasible path to a future filing rather than a terminal setback.
Background
Capricor sought FDA approval for deramiocel to preserve upper-limb function in Duchenne muscular dystrophy after prior FDA advisory committee concerns and an application amendment.
Ticker impact
FDA declined to approve Capricor’s deramiocel for Duchenne muscular dystrophy due to serious data integrity problems in a key trial.
Likely further downside pressure as investors reprice the probability of near-term approval and the value of the deramiocel program.
The article reports a direct FDA non-approval decision, cites the specific reason (data integrity problems), and notes shares down sharply in extended trading, indicating immediate repricing.
Market effects
Highlights heightened regulatory scrutiny around clinical data integrity for gene and cell therapies, potentially raising perceived approval risk across similar late-stage programs.
US biotech sentiment likely deteriorates for Duchenne and rare-disease cell therapy peers as traders reassess approval odds.
May influence global investors’ risk models for cell-therapy platforms and trial-quality governance, not limited to the US.
Counterpoint
Investors may view the denial as program-specific, with potential for resubmission if Capricor can address data integrity issues and refine the indication further.
Key entities
- companyCapricor Therapeutics
Biotech company whose experimental cell therapy deramiocel was denied by the US FDA for Duchenne muscular dystrophy.
- regulatorUS Food and Drug Administration (FDA)
US regulator that declined approval, citing serious data integrity problems in a key clinical trial.
- productderamiocel
Capricor’s experimental cell therapy being evaluated for Duchenne muscular dystrophy.


